CRB-913 - (CANYON-1)

August 4, 2026: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) said the last patient completed the last visit in CANYON-1, a Phase 1b dose-finding trial of CRB-913 for obesity, with topline data still expected in September 2026. CANYON-1 is a 16-week, double-blind, placebo-controlled, dose-ranging U.S. study in 240 obese, non-diabetic adults (NCT07310901), testing once-daily oral CRB-913 at 20 mg, 40 mg, and 60 mg versus placebo; treatment lasted 12 weeks plus 4 weeks of safety follow-up.

CRB-913 is described as a once-daily, peripherally restricted oral CB1 inverse agonist intended as a non-incretin obesity treatment. The company also highlighted preclinical data that CRB-913 showed 15-fold lower brain penetration than monlunabant in mice.

Corbus referenced its completed Phase 1a SAD/MAD study (completed December 2025): SAD enrolled 64 participants across 8 cohorts and MAD enrolled 48 across 4 cohorts, including an obese cohort. In the obese MAD cohort at 150 mg/day, all CRB-913-treated participants (n=9) and none on placebo (n=3) lost weight, with mean placebo-adjusted weight loss of 2.9% by Day 14. The company said CRB-913 was safe and well tolerated, with no reported vomiting, constipation, or nausea and negative daily neuropsychiatric assessments.